Teva Pharmaceutical Industries (TEVA) Cash from Financing Activities (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Cash from Financing Activities for 18 consecutive years, with $13.0 million the latest figure, recorded in Q1 2026.

• Quarterly Cash from Financing Activities rose 100.75% year-over-year to $13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$394.0 million (up 88.36% YoY) and the FY2025 annual result came in at -$2.2 billion, down 20.1% from the prior year.
• Cash from Financing Activities slipped to $13.0 million in Q1 2026 per TEVA's latest filing, from $40.0 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for TEVA reached as high as $40.0 million in Q4 2025 and fell as low as -$1.7 billion in Q1 2025.
• A 5-year average of -$458.0 million and a median of -$446.0 million in 2022 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities slumped 35400.0% — and 2025, when it jumped 105.93%.
• Year by year, Cash from Financing Activities stood at -$711.0 million in 2022, then advanced by 18.99% to -$576.0 million in 2023, then slipped by 17.01% to -$674.0 million in 2024, then surged by 105.93% to $40.0 million in 2025, then tumbled by 67.5% to $13.0 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $13.0 million, $40.0 million, and -$453.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.